## 1) What the Gilead–Arcellx deal *actually* signals (beyond the headline price) Gilead’s latest disclosure frames the Arcellx transaction as a deliberate move to **lock up a scarce, late-stage BCMA CAR‑T asset** and consolidate control ahead of what it characterizes as a meaningful commercial ramp. In its Feb. 23, 2026 8‑K, Gilead disclosed a signed merger agreement for **$115/share in cash plus a $5 CVR** tied to a sales milestone, with the CVR payable only if **cumulative worldwide anito‑cel sales exceed $6.0B by Dec. 31, 2029**—a structure that effectively “prices in” blockbuster ambition while offloading some commercialization risk onto sellers. ["$115.00 per Share"](0001104659-26-018314|0) ["$5.00 per CVR"](0001104659-26-018314|0) ["exceed $6,000,000,000"](0001104659-26-018314|0) Equally important: the same 8‑K links the M&A announcement to **FDA acceptance of the BLA** for anito‑cel in relapsed/refractory multiple myeloma, reinforcing that this isn’t “platform optionality”—it’s a bid to control a near-term commercial product. ["FDA of the Biologic License Application"](0001104659-26-018314|0) ["BCMA-targeting"](0001104659-26-018314|0) ## 2) Hidden “cell-therapy math”: why this deal can reprice the whole myeloma complex One line in the joint press release (filed as Exhibit 99.1) is the tell: Gilead explicitly says the transaction gives it **“Full Control”** and **eliminates “Profit-Share, Milestones, and Royalties.”** That is a direct admission that, at scale, *economics matter as much as efficacy* in CAR‑T—owning the asset (and the margin pool) is strategically cleaner than sharing it. ["Full Control"](0001104659-26-018314|3) ["Eliminating Profit-Share"](0001104659-26-018314|3) This is the “between-the-lines” alpha for peers: when a large-cap buyer is willing to pay up for BCMA exposure and then emphasizes margin recapture, it can tighten the market’s implied scarcity premium for other de-risked myeloma franchises—especially those with (i) proven demand, (ii) scaling manufacturing, and (iii) improving unit economics. ## 3) Why LEGN can become a “sympathy” beneficiary: CARVYKTI is already behaving like the category leader Legend’s most recent investor materials on file underscore that CARVYKTI is not a theoretical competitor—it is positioned as the commercial reference point in BCMA CAR‑T, with claims of leadership and expanding infrastructure. Legend states CARVYKTI is the **“top-selling CAR‑T in a single quarter,”** highlights **“>10,000 patients treated,”** and lays out manufacturing expansion with **multiple sites online**, a **“97% Manufacturing Success Rate,”** and **“10,000 annualized dose capacity in 2026.”** ["top-selling CAR - T"](0001171843-26-000257|1) ["10,000+ patients treated"](0001171843-26-000257|1) ["97% Manufacturing Success Rate"](0001171843-26-000257|1) ["10,000 annualized dose capacity"](0001171843-26-000257|1) Just as importantly for equity narratives, Legend frames 2026 as a **profitability inflection** year, including an expectation to achieve **“company-wide operating profit in 2026.”** In a tape that is increasingly rewarding “durable oncology cash flows” rather than distant pipelines, that messaging can make LEGN an obvious rotation target when a blockbuster-priced myeloma deal hits the news. ["Expected to achieve company - wide operating profit in 2026"](0001171843-26-000257|1) ## 4) The market’s likely trade (and the actionable takeaway) Even without assuming any single-stock move, the setup is straightforward: Gilead’s disclosed willingness to pay a premium for near-term BCMA CAR‑T exposure—and to highlight economics (control, profit-share removal) as a core rationale—can push traders and fundamental investors to **re-underwrite the value of “already scaled” myeloma winners**. ["definitive agreement to acquire"](0001104659-26-018314|3) ["Eliminating Profit-Share"](0001104659-26-018314|3) For LEGN specifically, the “hidden” angle is that Legend is communicating *execution readiness* (manufacturing capacity, turnaround time, site activation) at the same time the market is being reminded—via Gilead’s filing—that strategic buyers view BCMA CAR‑T as a must-own pillar. In that environment, LEGN can trade less like a single-product biotech and more like a **strategic franchise asset** that sits inside the same scarcity bucket. ["All Manufacturing Sites Now Online"](0001171843-26-000257|1) ["141 Activated Treatment Sites"](0001171843-26-000257|1) ["BCMA-directed CAR T-cell therapy"](0001104659-26-018314|3)

## 1) What the Gilead–Arcellx deal *actually* signals (beyond the headline price) Gilead’s latest disclosure frames the Arcellx transaction as a deliberate move to **lock up a scarce, late-stage BCMA CAR‑T asset** and consolidate control ahead of what it characterizes as a meaningful commercial ramp. In its Feb. 23, 2026 8‑K, Gilead disclosed a signed merger agreement for **$115/share in cash plus a $5 CVR** tied to a sales milestone, with the CVR payable only if **cumulative worldwide anito‑cel sales exceed $6.0B by Dec. 31, 2029**—a structure that effectively “prices in” blockbuster ambition while offloading some commercialization risk onto sellers. ["$115.00 per Share"](0001104659-26-018314|0) ["$5.00 per CVR"](0001104659-26-018314|0) ["exceed $6,000,000,000"](0001104659-26-018314|0) Equally important: the same 8‑K links the M&A announcement to **FDA acceptance of the BLA** for anito‑cel in relapsed/refractory multiple myeloma, reinforcing that this isn’t “platform optionality”—it’s a bid to control a near-term commercial product. ["FDA of the Biologic License Application"](0001104659-26-018314|0) ["BCMA-targeting"](0001104659-26-018314|0) ## 2) Hidden “cell-therapy math”: why this deal can reprice the whole myeloma complex One line in the joint press release (filed as Exhibit 99.1) is the tell: Gilead explicitly says the transaction gives it **“Full Control”** and **eliminates “Profit-Share, Milestones, and Royalties.”** That is a direct admission that, at scale, *economics matter as much as efficacy* in CAR‑T—owning the asset (and the margin pool) is strategically cleaner than sharing it. ["Full Control"](0001104659-26-018314|3) ["Eliminating Profit-Share"](0001104659-26-018314|3) This is the “between-the-lines” alpha for peers: when a large-cap buyer is willing to pay up for BCMA exposure and then emphasizes margin recapture, it can tighten the market’s implied scarcity premium for other de-risked myeloma franchises—especially those with (i) proven demand, (ii) scaling manufacturing, and (iii) improving unit economics. ## 3) Why LEGN can become a “sympathy” beneficiary: CARVYKTI is already behaving like the category leader Legend’s most recent investor materials on file underscore that CARVYKTI is not a theoretical competitor—it is positioned as the commercial reference point in BCMA CAR‑T, with claims of leadership and expanding infrastructure. Legend states CARVYKTI is the **“top-selling CAR‑T in a single quarter,”** highlights **“>10,000 patients treated,”** and lays out manufacturing expansion with **multiple sites online**, a **“97% Manufacturing Success Rate,”** and **“10,000 annualized dose capacity in 2026.”** ["top-selling CAR - T"](0001171843-26-000257|1) ["10,000+ patients treated"](0001171843-26-000257|1) ["97% Manufacturing Success Rate"](0001171843-26-000257|1) ["10,000 annualized dose capacity"](0001171843-26-000257|1) Just as importantly for equity narratives, Legend frames 2026 as a **profitability inflection** year, including an expectation to achieve **“company-wide operating profit in 2026.”** In a tape that is increasingly rewarding “durable oncology cash flows” rather than distant pipelines, that messaging can make LEGN an obvious rotation target when a blockbuster-priced myeloma deal hits the news. ["Expected to achieve company - wide operating profit in 2026"](0001171843-26-000257|1) ## 4) The market’s likely trade (and the actionable takeaway) Even without assuming any single-stock move, the setup is straightforward: Gilead’s disclosed willingness to pay a premium for near-term BCMA CAR‑T exposure—and to highlight economics (control, profit-share removal) as a core rationale—can push traders and fundamental investors to **re-underwrite the value of “already scaled” myeloma winners**. ["definitive agreement to acquire"](0001104659-26-018314|3) ["Eliminating Profit-Share"](0001104659-26-018314|3) For LEGN specifically, the “hidden” angle is that Legend is communicating *execution readiness* (manufacturing capacity, turnaround time, site activation) at the same time the market is being reminded—via Gilead’s filing—that strategic buyers view BCMA CAR‑T as a must-own pillar. In that environment, LEGN can trade less like a single-product biotech and more like a **strategic franchise asset** that sits inside the same scarcity bucket. ["All Manufacturing Sites Now Online"](0001171843-26-000257|1) ["141 Activated Treatment Sites"](0001171843-26-000257|1) ["BCMA-directed CAR T-cell therapy"](0001104659-26-018314|3)